GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: American Journal of Hematology, Wiley, Vol. 95, No. 11 ( 2020-11), p. 1235-1245
    Abstract: Polymerization of the sickle hemoglobin (HbS) is a key determinant of sickle cell disease (SCD), an inherited blood disorder. Fetal hemoglobin (HbF) is a major modulator of the disease severity by both decreasing HbS intracellular concentration and inhibiting its polymerization. However, heterocellular distribution of HbF is common in SCD. For HbS polymerization inhibition, the hypothesis of an “HbF per red blood cell (HbF/RBC) threshold” requires accurate measurement of HbF in individual RBC. To date, HbF detection methods are limited to a qualitative measurement of RBC populations containing HbF ‐ the F cells, which are variable. We developed an accurate method for HbF quantification in individual RBC. A linear association between mean HbF content and mean RBC fluorescence by flow cytometry, using an anti‐Human‐HbF antibody, was obtained from non‐SCD subjects presenting homogeneous HbF distribution. This correlation was then used to measure HbF/RBC. Hydroxyurea (HU) improves SCD clinical manifestations, mainly through its ability to induce HbF synthesis. The HbF distribution was analyzed in 14 SCD patients before and during HU treatment. A significant decrease in RBC population containing less than 2 pg of HbF/RBC was observed. Therefore, we tested associations for %RBC above different HbF/RBC thresholds and showed a decrease in the pathognomonic vaso‐occlusive crisis incidence from the threshold of 4 pg. This quantity was also correlated with the level of sickle RBC after in vitro deoxygenation. This new method allows the comparison of HbF/RBC distributions and could be a useful tool to characterize baseline patients HbF distribution and therapeutic response to HbF inducers.
    Type of Medium: Online Resource
    ISSN: 0361-8609 , 1096-8652
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1492749-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Transfusion Clinique et Biologique, Elsevier BV, Vol. 28, No. 4 ( 2021-11), p. S106-
    Type of Medium: Online Resource
    ISSN: 1246-7820
    Language: French
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2038528-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: American Journal of Hematology, Wiley, Vol. 91, No. 10 ( 2016-10), p. 1008-1013
    Abstract: Production of abnormal hemoglobin (HbS) in sickle‐cell disease (SCD) results in its polymerization in deoxygenated conditions and in sickled‐RBC formation. Dense RBCs (DRBCs), defined as density 〉 1.11 and characterized by increased rigidity are absent in normal AA subjects, but present at percentages that vary of a patient to another remaining stable throughout adulthood for each patient. Polymerized HbS has reduced affinity for oxygen, demonstrated by the rightward shift of the oxygen‐dissociation curve, leading to disturbances in oxygen transport. Ninety‐two SCD patients' total RBCs were separated into LightDRBC (LRBC) ( d   〈  1.11 g/mL) and DRBC fractions. Venous blood partial oxygen pressure and RBC‐fraction–deoxygenation and –reoxygenation Hb–oxygen‐equilibrium curves were determined. All patients took a 6‐minute walking test (6MWT); 10 had results before and after 〉 6 months on hydroxyurea. 6MWT time with SpO 2   〈  88% (TSpO 2   〈  88) assessed the physiological impact of exertion. Elevated mean corpuscular hemoglobin (Hb) concentrations, decreased %HbF, and 2,3‐bisphosphoglycerates in DRBCs modulated Hb–oxygen affinity. Deoxygenation and reoxygenation Hb–oxygen equilibrium curves differed between normal Hb AA and SS RBCs and between LRBCs and DRBCs, with rightward shifts confirming HbS‐polymerization's role in affinity loss. In bivariate analyses, 50% Hb saturation correlated positively with %DRBCs ( P   〈  0.0001, r 2  = 0.34) and negatively with %HbF ( P   〈  0.0001, r 2  = 0.25). The higher the %DRBCs, the longer the TSpO 2 88 ( P  = 0.04). Hydroxyurea was associated with significantly shorter TSpO 2   〈  88 ( P  = 0.01). We report that the %DRBCs directly affects SCD patients' SpO 2 during exertion; hydroxyurea improves oxygen affinity and lowers the %DRBCs. Am. J. Hematol. 91:1008–1013, 2016. © 2016 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 0361-8609 , 1096-8652
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 1492749-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 134, No. Supplement_1 ( 2019-11-13), p. 1008-1008
    Abstract: Introduction: Fetal hemoglobin (HbF) expression is a major modulator of sickle cell disease (SCD) severity by decreasing the HbS polymerization. However, the distribution of HbF in red blood cells (RBC) is heterogeneous in SCD patients. In the hypothesis of an HbF "threshold" in RBCs for inhibiting the HbS polymerization, accurate measurement of the HbF content in each red blood cell (HbF/RBC) is mandatory. To this purpose we developed a new and accurate method allowing the direct measurement of HbF content per RBC. Thanks to it, as a proof of concept, we analyzed HbF distribution and content in RBC from SCD patients before and after 6 months of treatment by hydroxyurea (HU). To determine if a threshold of HbF/RBC could modulate SCD, we analyzed the associations between the %RBC reaching different thresholds of HbF (in picograms), and biological parameters and the incidence of severe VOC. Methods: 14 SCD (βS/βS or βS/β0) patients were included to study HbF distribution during HU for a period of 6 months. RBCs were collected during each outpatient visit (Week 0, Week 2, Week 4, Week 12, and ≥ Week 24). HbF content was measured in RBCs using an anti-Human-HbF antibody by flow cytometry. Normalized RBC fluorescence intensity was then converted in picograms of HbF/RBC by using the linear association between mean HbF content and mean RBC fluorescence obtained from subjects presenting homogeneous HbF distribution (patients with hereditary persistence of HbF (HPFH), or β-Thalassemia or δβ-Thalassemia). Quantitative analysis were performed before and during HU treatment to characterize the response by comparing percentages of RBC classes based on different ranges of HbF/RBC during HU treatment. We therefore analyzed the associations between HbF/RBC thresholds (%RBC containing at least 2, 4, 6, 8, 10 or 20 pg HbF) and biological parameters before and ≥ 6 months of HU treatment. Finally HbF/RBC thresholds at Week 0 were compared to the incidence of hospitalized VOC within 3 years before W0, and HbF/RBC thresholds at Week 24 were compared to the incidence of hospitalized VOC within 3 years after W24 at a stable dose. Results: After 6 months of HU, mean %HbF, assessed by HPLC, raised from 6.16% (±3.5) to 15.2% (±8.7) (mean ± standard deviation). Quantitative analysis of HbF/RBC revealed a statistically significant decrease between D0 and ≥M6 of 24% of RBCs containing less than 2 pg (p = 0.0015) and a 2-fold increase of RBCs containing between 2 and 4 pg (p = 0.0025) (Friedman test). For biological parameters we observed an increase in mean %HbF, MCV and MCH and a decrease in RBC count significantly associated (p 〈 0.001 - Spearman test) with %RBC containing ≥ 2 pg of HbF. The incidence of VOC within 3 years after HU treatment was not statistically significant than during the 3 years before (p = 0.4414 - Wilcoxon test). VOC incidence under treatment decreased in 6/14 patients, did not change in 4/14 and increased in 4/14. The incidence of VOC over 3 years was not associated with the %HbF assessed by HPCL (r = -0.0358; p = 0.8564 - Spearman test). We observed a statistically significant correlation between the incidence of VOC over 3 years and the HbF threshold of 4 pg (r = -0.5068; p = 0.0059). We therefore determined the percentage of RBCs by thresholds of HbF, associated to ≤ 1 VOC over 3 years (Table 1). For example, if more than 20% RBCs have ≥ 4 pg of HbF, we calculated a sensitivity and a specificity of 58.3% and 100% respectively, and a positive and a negative predictive value of 100.0% and 76.2% respectively, to have ≤ 1 VOC over 3 years. Conclusion: Our results strengthen the hypothesis that the percentage of RBC above a threshold of HbF is the important parameter to measure. These results need to be replicated in a larger cohort but they open up interesting prospects for analysis of new therapeutic efficacy, including gene therapy and HbF inducers. Disclosures Galactéros: Addmedica: Membership on an entity's Board of Directors or advisory committees. Bartolucci:Agios: Membership on an entity's Board of Directors or advisory committees; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees; HEMANEXT: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; AddMedica: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2019
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 2713-2713
    Abstract: Production of abnormal hemoglobin (HbS) in sickle-cell disease (SCD) results in its polymerization in deoxygenated conditions and in sickled-RBC formation. Dense RBCs (DRBCs), defined as density 〉 1.11 and characterized by increased rigidity, viscosity and HbS concentration (main polymerization factor), are absent in normal AA subjects, but present at percentages that vary from 1 SCD patient to another but remain stable throughout adulthood for each patient. Polymerized, but not nonpolymerized, HbS has reduced affinity for oxygen, demonstrated by the rightward shift of the oxygen-dissociation curve, leading to disturbances in oxygen transport. We recently described a correlation between %DRBCs and some clinical SCD manifestations. Notably, some SCD patients have unexplained, very low oxygen saturation (SpO2), without heart or lung dysfunctions. %DRBC variability within SCD patients could be the main pathophysiological explanation of those manifestations. This study was undertaken to determine whether a link exists between the %DRBCs and Hb affinity for oxygen, and to look for a potential clinical implication for SCD patients. 92 patients (44.6 ± 7.7 years; 51 women and 41 men) were included in the study. Blood samples were obtained at steady state to measure hemorheological and hematological parameters. Using a Percoll-gradient fractionation method, total RBCs were separated into non-DRBCs (NDRBC) (d 〈 1.11) and DRBCs (d 〉 1.11) fractions. The %DRBCs was determined using the phthalate-gradient method. P50 in venous blood gases was measured with a radiometry analyzer. Oxygen-affinity curves of Hb dissociation and association in RBC fractions were obtained with dual wavelength spectrophotometry. All patients had a 6-minute walking test (6MWT) and 10 of them (38.1 ± 6.1 years; 6 men and 4 women) had done so before and after 〉 6 months ( 〉 6M) on hydroxyurea (HU). Times 〈 90% and 〈 88% transcutaneous SpO2 of Hb and a SpO2 decrease ≥4% during the test (delta SpO2 〉 4%) were evaluated to investigate the physiological impact on patients during exertion. Patients, divided into quartiles according to their values (Q1: 0–25th centile, Q2–Q3: 25th–75th centiles, and Q4: 〉 75th centile), were analyzed for the times 〈 88% SpO2, 〈 90% SpO2 and with delta SpO2 〉 4%, for the distance walked. DRBCs had increased MCHC and decreased %HbF and 2,3 DPG, leading to more polymerization and modulation of Hb affinity for oxygen, compared to NDRBCs. Moreover, dissociation and association curves of SS RBC fractions differed (compared to AA RBCs), with rightward shifts of NDRBCs and, more importantly, DRBC-association curves, thereby confirming the role of HbS polymerization in the loss of affinity (Fig 1). Bivariate analysis showed that the P50 was positively correlated with the %DRBCs (P 〈 0.0001, r²=0.34), reflecting a link between the total Hb–oxygen affinity and %DRBCs in SCD patients. Conversely, P50 and %HbF were negatively correlated (P 〈 0.0001, r²=0.25). The clinical impact of %DRBCs was studied with the 6MWT. Q4 patients for the times 〈 90% SpO2 and 〈 88% SpO2 had higher %DRBCs than Q1 patients (P=0.03 and P=0.04, respectively). No between-group differences were observed for the times 〈 90% SpO2 and 〈 88% SpO2 for Hb or %HbF. Finally, in agreement with our previous demonstration that HU strongly decreased the %DRBCs 〉 M6 of therapy and that the %DRBCs impacted the time at low SpO2, the 10 SCD patients' 6MWT results before and 〉 M6 of HU therapy showed significantly decreased times 〈 90% SpO2 (P=0.002) and 〈 88% SpO2 (P=0.01) (Fig 2), and with delta SPO2 〈 4% (P=0.02). In conclusion, according to our results, the %DRBCs directly affects SCD patients' SpO2 during exercise; HU improves oxygen affinity in correlation with the %DRBC decline. Figure 1 Under standard in vitro conditions (pH=7.4, pCO2 40 mm Hg, 37°C), the positions of oxyhemoglobin (A) dissociation curves of the different whole blood RBC fractions of an SS SCD patient and an AA control, and AA NDRBCs and SS DRBCs; (B) deoxygenation (–) and reoxygenation (- -) curves of the AA RBC fraction; (C) deoxygenation (–) and reoxygenation (- -) curves of the SS NDRBC fraction; (D) deoxygenation (–) and reoxygenation (- -) curves of the SS DRBC fraction. Figure 1. Under standard in vitro conditions (pH=7.4, pCO2 40 mm Hg, 37°C), the positions of oxyhemoglobin (A) dissociation curves of the different whole blood RBC fractions of an SS SCD patient and an AA control, and AA NDRBCs and SS DRBCs; (B) deoxygenation (–) and reoxygenation (- -) curves of the AA RBC fraction; (C) deoxygenation (–) and reoxygenation (- -) curves of the SS NDRBC fraction; (D) deoxygenation (–) and reoxygenation (- -) curves of the SS DRBC fraction. Figure 2 Comparison of times 〈 90% SpO2, 〈 88% SpO2 and with delta SpO2 〉 4% before and 〉 M6 of HU. Figure 2. Comparison of times 〈 90% SpO2, 〈 88% SpO2 and with delta SpO2 〉 4% before and 〉 M6 of HU. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...